Skip to main content
. 2014 Feb 12;3(2):390–396. doi: 10.1002/cam4.197

Table 3.

Recurrence of HCC in patients who did not receive antiviral therapy.

Pt Year of Dx Age Sex Tumor size (cm), site Child-pugh class Initial tumor ablation Antiviral therapy Recurrence (months) Retreatment Survival (months) Status
1 1991 66 M 2 Rt C TACE None 2 TACE 3 Dead
2 1994 58 M 3 Rt A Resection None 20 Resectionx2 36 Dead
3 1996 46 M 4 Lt A Cryoablation None 5 Cryo, TACE 17 Dead
4 1996 53 M 3 Rt A Cryoablation None 5 TACE, chemo 9 Dead
5 1996 53 M 4 Rt A Resection None 12 TACEx2 16 Dead
6 1997 59 M 1 Rt B PCEI None 2 ChemoRx 6 Dead
7 1999 48 M 2.5 Rt C TACE None 3 TACE multiple 16 Dead
8 1999 60 M 2.5 Lt A TACE, RFA None 9 TACE 17 Dead
9 1999 53 M 6.9 Rt B TACE None 6 Incomplete Ablation, multiple times 6 Dead

HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PCEI, percutaneous ethanol injection; RFA, radiofrequency ablation.